| Dr Lucy Fox, MD | |
|
201 Cedar St Se, Suite 800, Albuquerque, NM 87106-4917 | |
| (505) 563-2800 | |
| (505) 563-2821 |
| Full Name | Dr Lucy Fox |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Nephrology |
| Location | 201 Cedar St Se, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558385930 | NPI | - | NPPES |
| E5606 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 88-169 (New Mexico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lucy Fox, MD 201 Cedar St Se, Suite 800, Albuquerque, NM 87106-4917 Ph: (505) 563-2800 | Dr Lucy Fox, MD 201 Cedar St Se, Suite 800, Albuquerque, NM 87106-4917 Ph: (505) 563-2800 |
News Archive
Elbit Imaging Ltd. ("Elbit" or the "Company") announced today, following its announcements dated June 23, 2014 and October 14, 2014, that its 62.25% owned subsidiary, Plaza Centers N.V. ("Plaza"), announced that Plaza's shareholders have approved the proposed rights offering (the "Rights Offering") which forms part of Plaza's restructuring plan.
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A Mayo Clinic research team has found evidence suggesting that the controversial practice of ovary removal in premenopausal women to prevent ovarian cancer should be discontinued in women who are not at high risk of cancer.
A unique project to develop technology to drive fast and effective drug discovery was announced today by Business Secretary Greg Clark. Based at the Rosalind Franklin Institute in Harwell, Oxfordshire, this new project will pioneer fully-automated hands-free molecular discovery to produce new drugs up to ten times faster and transform the UK's pharmaceutical industry.
› Verified 3 days ago
Dr. Alberto Aguayo Rico, M.D, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 401 San Mateo Blvd Se, Albuquerque, NM 87108 Phone: 505-462-7333 Fax: 505-462-7440 | |
Peter Guido, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 4700 Jefferson St Ne, Ste 800, Albuquerque, NM 87109 Phone: 505-872-6000 Fax: 505-872-6003 | |
Kenneth A Bell, DO Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2901 Transport St Se, Albuquerque, NM 87106 Phone: 505-262-7110 Fax: 505-262-7308 | |
Joseph F. Oser, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1501 San Pedro Dr Se, Albuquerque, NM 87108 Phone: 505-265-1711 | |
Dr. Stanley Zissman Berman, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 7416 Vista Del Arroyo Ave Ne, Albuquerque, NM 87109 Phone: 505-884-7270 | |
Huyentrang Vu, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: Unm Hospital Internal Medicine, 2211 Lomas Blvd Ne, Albuquerque, NM 87131 Phone: 505-272-6225 | |
Tamara Goodman, MD Nephrology Medicare: Medicare Enrolled Practice Location: 4901 Lang Ave Ne, Albuquerque, NM 87109 Phone: 505-842-8171 |